Bethesda, Maryland (ots/PRNewswire) - - Company Expects Four Antibodies in Clinical Development by End of 2007 - Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for the treatment of cancer, inflammatory and autoimmune diseases, announced today the promotion of Carsten Reinhardt, M.D. from Senior Vice President of Clinical ...
Bethesda, Maryland, and Roskilde, Denmark (ots/PRNewswire) - Micromet, Inc. (Nasdaq: MITI) and Nycomed today announced an agreement under which the two companies will collaborate on the development of anti-GM-CSF antibodies that may be useful for the treatment of inflammatory and autoimmune diseases. The lead ...
Carlsbad, California (ots/PRNewswire) - - Start of Phase 1 Clinical Trial Planned for the Second Half of This Year Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development of novel and proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, and ...
Carlsbad, California (ots/PRNewswire) - Micromet, Inc. (Nasdaq: MITI) ("Micromet" or the "Company"), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced its financial results for the fourth quarter and the full year ended December 31, 2006. As a ...